Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
budoprutug (TNT119) / Eliem Therap
NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)	Terminated	2	1	US	VB119	Tenet Medicines	Minimal Change Disease, Focal Segmental Glomerulosclerosis	05/23	10/23
NCT04652570: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy	Active, not recruiting	1/2	6	US	VB119	Tenet Medicines	Membranous Nephropathy	11/23	08/24
NCT06570434: Phase 1b/2a in SLE With Budoputug	Not yet recruiting	1/2	40	NA	budoprutug	Tenet Medicines	Systemic Lupus Erythematosus, SLE, B Cells	12/26	04/27